Core Viewpoint - The article discusses the performance and management of the Rongtong Health Industry Flexible Allocation Mixed Fund A/B, highlighting its net asset growth and the background of its fund manager, Wan Minyuan [1][2]. Fund Performance - As of June 30, 2025, the net assets of the Rongtong Health Industry Flexible Allocation Mixed Fund A/B reached 2.074 billion yuan, reflecting a 1.92% increase from the previous period [1]. - The fund's recent performance includes a 15.0% return over the last three months and a 19.86% return over the past year, with a cumulative return of 166.1% since inception [2]. Fund Manager Background - Wan Minyuan, the fund manager, holds a PhD in Biomedical Science from Sichuan University and has extensive experience in the investment sector, having worked at various securities firms and investment management companies since 2011 [1]. Fund Holdings - The top ten stock holdings of the fund include Yixin Tang, Aibo Medical, Sanyou Medical, Jianzhijia, Kaili Medical, Yangguang Nuohuo, Dongfang Biological, Puri Eye Care, Meihua Medical, and Meinian Health, with a combined holding percentage of 57.00% [2]. Company Overview - Rongtong Fund Management Co., Ltd. was established in May 2001 and is based in Shenzhen, focusing on capital market services, with a registered capital of 125 million yuan [2].

该基金属于灵活配置型基金，长期投资于医药医疗股票。截至7月17日，单位净值为2.661元。基金经理是万民远，目前管理5只基金近一年均为正收益。其 中，截至7月17日，融通价值成长混合A近一年复权单位净值增长率最高，达51.66%；融通医疗保健行业混合A/B最低，为12.27%。 基金管理人在二季报中表示，本基金按照基金合同规定要求，精选赛道及成长性较好且估值相对较低的板块及个股进行重点配置，并适时调整组合结构。我 们依然坚持顺着中国医药产业结构升级和医疗需求修复的方向寻找投资机会。重点从创新引领的产业升级及进口替代、院内医疗复苏及足够悲观定价等几个 角度精选个股。目前本基金重点配置创新（创新药及产业链、创新器械）+复苏（消费医疗、零售及中药等）及低 PB 类资产。 AI基金融通健康产业灵活配置混合A/B（000727）披露2025年二季报，第二季度基金利润1.79亿元，加权平均基金份额本期利润0.2151元。报告期内，基金 净值增长率为8.97%，截至二季度末，基金规模为20.74亿元。 截至6月30日，基金近三年夏普比率为0.1159，位于同类可比基金48/105。 截至7月17日，基金近三年最大回撤为45 ...

Group 1 - Kanyuan Pharmaceutical (600557.SH) released its 2024 annual report on April 3, 2025, indicating that 125 institutional investors disclosed holding A-shares, totaling 292 million shares, which accounts for 50.25% of the total share capital [1] - The top ten institutional investors include Jiangsu Kanyuan Group Co., Ltd., Lianyungang Kangbeier Medical Equipment Co., Ltd., Central Huijin Asset Management Co., Ltd., and others, with a combined holding ratio of 47.38%, showing a decrease of 1.85 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, five funds reported a decrease in holdings compared to the previous quarter, with a total reduction of 1.49% [2] - A total of 111 new public funds were disclosed this period, including funds such as Rongtong Health Industry Flexible Allocation Mixed A/B and Southern CSI 1000 ETF [2] - Four public funds were not disclosed this period, including various funds under the Fangzheng Fubang brand [2]